Universität zu Köln

Riet, Tobias and Abken, Hinrich (2015). Chimeric antigen receptor T cells: power tools to wipe out leukemia and lymphoma. Expert Rev. Hematol., 8 (4). S. 383 - 386. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1747-4094

Full text not available from this repository.

Abstract

Adoptive cell therapy for malignant diseases is showing promise in recent early-phase trials in the treatment of B cell leukemia/lymphoma. Genetically engineered with a tumor-specific chimeric antigen receptor, patient's T cells produce lasting and complete leukemia regression. However, treatment is associated with some toxicity which needs our attention and the field still faces some hurdles at the scientific, technologic and clinical levels. Surmounting these obstacles will establish chimeric antigen receptor T cell therapy as a powerful approach to cure hematologic malignancies, paving the way for the treatment of other common types of cancer in the future.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Riet, Tobias UNSPECIFIED UNSPECIFIED UNSPECIFIED Abken, Hinrich UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-398078
DOI:	10.1586/17474086.2015.1043884
Journal or Publication Title:	Expert Rev. Hematol.
Volume:	8
Number:	4
Page Range:	S. 383 - 386
Date:	2015
Publisher:	TAYLOR & FRANCIS LTD
Place of Publication:	ABINGDON
ISSN:	1747-4094
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PERSISTENCE; REMISSIONS; MALIGNANCY; CANCER Multiple languages Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/39807